Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Trade Desks prolonged slide to multiyear lows is drawing attention amid concerns about slowing ad spending and growth, competition from Amazon and other platforms, and the outlook after weak guidance. Traders are sharply divided between expecting more downside and viewing the selloff as overdone, while many criticize CEO Jeff Green and the companys incentive package; speculation that Apples Safari changes are an immediate catalyst remains unconfirmed.

Iovances raised full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving a sharp rally. Traders are broadly bullish and debating whether short covering is amplifying the move, while some flag profit-taking and possible dilution; many also point to upcoming lung-cancer data as a potential catalyst.

Competition from Kalshi and Polymarket is driving debate over whether prediction markets are taking wagering share from traditional sportsbooks, with legal challenges over sports event contracts adding uncertainty. Bears worry about pressure on DraftKings margins and customer growth, while bulls point to rising DKeX volume and potential benefits if rivals face tighter state regulation.

FICO is drawing attention after FHFA changes put VantageScore alongside FICO on a unified Fannie Mae and Freddie Mac mortgage-pricing grid, raising concerns that competition could erode FICOs long-standing mortgage-scoring advantage. Traders are divided between expecting further pressure on pricing and market share and viewing the selloff as an overreaction given FICOs continued business strength.

Carnivals quarterly earnings beat and raised full-year outlook, alongside record customer deposits and strong 2027 bookings, sparked a sharp rally and lifted other cruise stocks. Bulls cite resilient demand, while skeptics point to fuel costs and weaker near-term guidance as ongoing risks.

A pause in the DEAs marijuana-rescheduling proceeding, amid questions about gaps in federal drug-classification procedures, has delayed expectations for the administrative law judges recommendation on Schedule III. Traders are frustrated by the uncertainty, while others view the pause as procedural and expect rescheduling to continue; its timing and outcome remain unsettled.

AstraZenecas sizable strategic investment in Summit and collaboration to study ivonescimab combinations have drawn attention, with traders viewing the deal as validation of the cancer-drug program and relief from financing concerns. Others point to dilution and stress that the agreement is not a buyout and does not resolve the separate FDA decision risk.

uniQure is selling off after four-year AMT-130 data showed less slowing of Huntingtons disease progression than the three-year results, with the 48-month cUHDRS result not statistically significant. Traders are debating whether this weakens confidence in the treatments durability or is less consequential because the BLA is based on the stronger three-year data; some view the drop as an overreaction, while others see meaningful efficacy concerns.

ICP is drawing attention after a sharp rebound and a push through a key technical resistance level, with traders debating whether the move can hold or will fade. Bullish holders also point to reported Pakistan government app deployments and ICPs decentralized cloud and AI infrastructure, while skeptics question adoption and the rallys staying power.

A Bank of America upgrade and higher price target are driving attention, with the analyst citing potential benefits to Magnite from Google ad-tech remedies that could give independent exchanges a fairer shot at ad spend. Traders are mostly welcoming the upgrade and share-price jump, though some caution that similar upgrade-driven rallies have faded before.